• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks

    GenMark Diagnostics Schedules Third Quarter 2016 Financial Results Conference Call

    Chelsea Pratt
    Oct. 21, 2016 12:26AM PST
    Medical Device Investing

    GenMark Diagnostics today announced that it plans to release its third quarter earnings results after market close on Thursday, November 3, 2016.

    GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 3, 2016. Management will hold a conference call to review the Company’s financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com
    under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 3270495 approximately five minutes prior to the start time.
    ABOUT GENMARK DIAGNOSTICS
    GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of automated,
    multiplex molecular diagnostic testing systems that detect and measure
    DNA and RNA targets to diagnose disease and optimize patient treatment.
    Utilizing GenMark’s proprietary eSensor® detection
    technology, GenMark’s eSensor XT-8® system is designed to
    support a broad range of molecular diagnostic tests with a compact,
    easy-to-use workstation and self-contained, disposable test cartridges.
    The eSensor detection technology is also incorporated into GenMark’s
    sample-to-answer system, ePlex®. For more information, visit www.genmarkdx.com.

    canadadiagnostic testsconference callfinancial resultsgenmark diagnosticsmolecular diagnostic testing
    The Conversation (0)
    Go Deeper
    AI Powered
    liquid sample testing vials in a lab

    5 Genetic Testing Stocks

    Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations

    Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×